Cypherpunk Expands Zcash Holdings by $29 Million to 290,062 ZEC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Source: PRnewswire
- Strategic Expansion: Cypherpunk Technologies has acquired an additional 56,418.09 ZEC for approximately $29 million, bringing its total Zcash holdings to 290,062.67 ZEC, which represents about 1.76% of the total circulating supply, indicating the company's ongoing investment and confidence in the privacy technology market.
- Cost Control: The average purchase price for this acquisition was $514.02 per ZEC, significantly higher than the cumulative average cost of $334.41, reflecting the company's focus on asset value amid market volatility.
- Market Positioning: CIO Will McEvoy stated that Cypherpunk aims to accumulate 5% of the Zcash network, and as its holdings grow, the company will further solidify its strategic position in the privacy market, likely attracting more investor interest.
- Technological Development: By continuously increasing its ZEC holdings, Cypherpunk is not only establishing a strong financial foundation in the digital asset space but also plans to expand the application of its privacy-preserving technologies, driving long-term shareholder value growth.
Analyst Views on CYPH
About CYPH
Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
